Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2005

View Archived Issues

Vav3: preclinical data identifies a potential target for the treatment of osteoporosis

CREB2 inhibition represents an important procognitive mechanism for SGS-742

Natural marine products as treatments for inflammatory bowel disease

Novel use for sodium nitrite: preservation of tissues and organs

Results of DB-289 formulation safety study

Enrollment completed in phase II study of Leukine for Crohn's disease

Acologix advances AC-100 into phase II in dentistry

Corcept starts new phase III trial with mifepristone in PMD

Encouraging preclinical toxicity results for alagebrium

Six-month data for Vascular Wrap paclitaxel-eluting mesh

RTA-744 enters clinical development

LR-103 to be tested in patients with chronic kidney disease

MC-1 shows preclinical potential for hypertriglyceridemia

Oral-lyn launch planned this year

FDA approves Cangene's Vaccinia immune globulin

Draxis updates Fibrimage program

Antiatherogenic effects of estrogen + lovastatin in ovariectomized LDLR-/- mice

ACAT2 inhibition with specific antisense oligonucleotides reduces atherogenic lipoprotein in mice

Proinflammatory adenosine A2B receptor induced in the aortic endothelium of diabetic mice

HIV-1 immunogen + CpG ODN prevents HIV infection in a novel Trimera mouse model of HIV-1 infection

IDE approval for Guidant's Xience drug-eluting stent trial

New therapeutics for cancer disclosed in recent patents

Transition Therapeutics updates progress of lead programs

New treatment option for macular degeneration disclosed by Nippon Soda

Zarnestra requires phase III data for approval

Triglide receives FDA approval

Diovan receives E.U. approval for treatment of heart attack survivors

Amgen submits sBLA for Aranesp extended dosing

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 16, 2025.
Atai Therapeutics discovers new 5-HT2A receptor partial agonists
BioWorld Science
Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...
PHD inhibitors reported in Akebia Therapeutics patent
BioWorld Science
Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.
FDA wants more data for Otsuka’s sNDA in PTSD
BioWorld
The U.S. FDA is insisting that another study is needed to bolster the sNDA for Rexulti (brexpiprazole) from Otsuka Pharmaceutical Co. Ltd. in treating adults with...